Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 11Neoplasm, Residual 2Triple Negative Breast Neoplasms 1Recurrence 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Myeloid 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1Carcinogenesis 1Breast Neoplasms 1

Interventions

Standard of Care 5Specimen Handling 4Practice Guidelines as Topic 4Methods 4Educational Status 3Early Intervention, Educational 3Cyclophosphamide 3Sentinel Lymph Node Biopsy 2Paclitaxel 2Magnetic Resonance Imaging 2Interviews as Topic 2Genetic Counseling 2Exercise 2Drug Therapy 2Diet Therapy 2veliparib 1toripalimab 1sacituzumab govitecan 1pegfilgrastim 1olaparib 1Vorinostat 1Videotape Recording 1Tablets 1Surveys and Questionnaires 1STA 9090 1Restore polishing paste 1Resistance Training 1Radiotherapy 1Radiosurgery 1Radiation Dose Hypofractionation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Triple Negative Breast Neoplasms × Azacitidine × Clear all
NCT01292083 2014-02-06

Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

University of Southern California

Phase NA Withdrawn
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡